ScripBiopharmaceutical companies remained on the hunt for cancer antibody-drug conjugate assets this summer, as deals revolving around ADCs accounted for five of 12 cancer-related deals, according to Biome
ScripDomestic licensing deals for homegrown innovative drugs in China posted a spike in July, as drug makers with established commercialization capabilities replenished their late-stage pipelines and resea
ScripMEI Pharma, Inc. said on 22 July that its board of directors unanimously agreed to hire a financial consultant that can help the company assess strategic alternatives to maximize the value of its ass
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Helsinn Extends Akynzeo Marketing